However, there is growing concern about the emergence of resistance to imatinib and other TKIs attributable to amplifications or mutations in the bcr-abl gene, clonal evolution, and the heterogeneous activity of BCR-ABL on CML cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.